European Pharmaceutical Review

SEPTEMBER 14, 2023

The pharmaceutical firm is investing greatly in its existing infrastructure to facilitate the shift to renewable gas and support a transition to 100 percent renewable energy. This includes its Macclesfield campus, the UK’s largest pharma manufacturing site.

Manufacturing 111

Manufacturing Medicine Pharmaceutical manufacturing Pharma 111

European Pharmaceutical Review

NOVEMBER 10, 2023

Novo Nordisk has announced plans to invest over 42 billion Danish kroner (nearly £5 billion) starting in 2023, to expand its manufacturing facilities in Kalundborg, Denmark. According to the pharma company , the financing will add to global capacity: from manufacturing of active pharmaceutical ingredients (API) through to packaging.

Manufacturing 111

Manufacturing Pharmaceutical manufacturing Pharmaceutical Medicine 111

European Pharmaceutical Review

SEPTEMBER 26, 2022

AbbVie , an international R&D biopharmaceutical enterprise has celebrated its 20th anniversary by investing in extensive renovations at its manufacturing site in Cork, Ireland. The €60 million expansion will open 70 new jobs in sterile manufacturing, quality control and engineering in 2025.

Manufacturing 98

Manufacturing Pharmaceutical manufacturing Biopharma Engineering 98

European Pharmaceutical Review

SEPTEMBER 28, 2023

A notable milestone was Moderna’s announcement in April that it had, following finalisation of a ten-year strategic partnership with the UK Government, commenced construction of its mRNA vaccine manufacturing technology centre.

Manufacturing 98

Manufacturing Government Pharmaceutical manufacturing Pharmaceutical 98

European Pharmaceutical Review

DECEMBER 18, 2023

In 2023, the pharma industry has] witnessed tremendous advances in CAR T-cell immunotherapy of solid tumours” Another treatment modality that has witnessed significant advancement this year in the pharmaceutical industry, is cell and gene therapy. According to CPI, the facility is set to be completed in late 2025.

Manufacturing 98

Manufacturing Food and Drug Administration Medicine Pharmaceutical manufacturing 98

pharmaphorum

NOVEMBER 25, 2022

The Parma site, as yet only nine months into construction, is due to become operational from 2024, with FDA, IFA, and EMA approvals due to be sought for 2025. In brief, the European plan for Chiesi is in-house drug development of biologicals and rare disease targeting.

Pharmaceutical 94

Pharmaceutical Manufacturing Medicine Competition 94

PM360

AUGUST 9, 2022

billion in 2025. Pharma Manufacturer Solutions. GM of Manufacturer Solutions. 1 GoodRx’s partnerships with pharma manufacturers and other key stakeholders in the healthcare industry enable them to offer discounts which have helped patients fill at least 80 million prescriptions that they otherwise could not afford.

Prescription 105

Prescription Medical Patients Side effects 105